DUPIXENT was studied in 2 pivotal trials of adult patients with prurigo nodularis

PRIME and PRIME2 assessed the effect of DUPIXENT on itch improvement and nodule
clearance.1,2

3X

as many patients in PRIME had
significantly reduced itch at
Week 24 (60% with DUPIXENT
vs 18% with placebo; P<0.001,
primary endpoint)1,2

PRIME2

37% of DUPIXENT patients achieved a meaningful
response at Week 12 vs 22% with placebo; P=0.022
(primary endpoint). At Week 24, 58% of DUPIXENT
patients achieved significant itch relief vs 20% with
placebo; P<0.001 (secondary endpoint)1,2

VIEW WI-NRS Results

2.5X

as many patients in PRIME achieved
significant nodule clearance
(IGA PN-S 0 or 1) at Week 24
(48% with DUPIXENT vs 18% with
placebo; P<0.001, secondary endpoint)1,2

PRIME2

45% of DUPIXENT patients similarly achieved
significant nodule clearance (IGA PN-S 0 or 1) at
Week 24 vs 16% with placebo; P<0.001
(secondary endpoint)1,2

VIEW IGA PN-S RESULTS

Demonstrated safety
profile1

  • Most common adverse reactions in adult patients with prurigo nodularis (incidence ≥2%) are:
    • Nasopharyngitis
    • Conjunctivitis
    • Herpes infection
    • Dizziness
    • Myalgia
    • Diarrhea
  • No patients treated with DUPIXENT (0%) discontinued treatment due to adverse events vs 3% with placebo
    • Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment

EXPLORE SAFETY
PROFILE

IGA PN-S, Investigator’s Global Assessment PN-
Stage; WI-NRS, Worst Itch numerical rating scale.

Dosage and administration

Thinking about prescribing DUPIXENT? Find the
information you need to get started.

View administration Options